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Abstract
Clobazam (Castillium1, Urbanil1), a benzodiazepine often used as an anxiolytic and in the treatment of epilepsy, is
considered a relatively safe drug. The authors present a fatal case with a 49-year-old female, found dead at home. She had been
undergoing psychiatric treatment and was a chronic alcoholic. The autopsy findings were unremarkable, except for multivisceral
congestion, steatosis and a small piece of a plastic blister pack in the stomach. Bronchopneumonia, bronchitis and bronchiolitis
were also diagnosed. Anhigh-performance liquid chromatography (HPLC)/diode array detector (DAD)/mass spectrometry
detection (MSD) with electrospray method was developed in order to detect, confirm and quantify clobazam in the post-mortem
samples. In the chromatographic separation, a reversed-phase column C18 (2:1 150 mm, 3.5 mm) was used with a mobile
phase of methanol and water, at a 0.25 ml/min flow rate. Carbonate buffer (pH 10.5) and 20 ml of prazepam (100 mg/ml) as
internal standard were added to the samples. A simple and reliable liquid–liquid extraction method for the determination of
clobazam in post-mortem samples was described. Calibration curves for clobazam were performed in blood, achieving linearity
between 0.01 and 10 mg/ml and a detection limit of 1.0 ng/ml. The clobazam concentration found in post-mortem blood was
3.9 mg/ml, higher than the reported therapeutic concentration (0.1–0.4 mg/ml). The simultaneous acquisition by photodiode
array detection and mass spectrometry detection results allowed benzodiazepines to be identified with sufficient certainty.
An examination of all the available information suggested that death resulted from respiratory depression due to clobazam
toxicity.
# 2004 Elsevier Ireland Ltd. All rights reserved.
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1. Introduction
Benzodiazepines are among the most widely prescribed
drugs and are used in the treatment of stress, anxiety-induced
depression, panic and sleep disorders, muscle spasms, alco-
hol withdrawal and seizures [1]. Unfortunately, they are
often subject to overdose in suicide attempts and are fre-
quently encountered in emergency intoxication episodes and
drugs-of-abuse testing.
Clobazam (Castillium1, Urbanil1) is a new antiepileptic
drug effective with most varieties of seizures and epilepsies
in both short-term and long-term treatment [2,3]. It is the
first 1,5-benzodiazepine that has nitrogen atoms in positions
1 and 5 of the heterocyclic ring, whose chemical structure
was designed to give it a different pharmacological profile
from that of 1,4-benzodiazepines [4]. Clobazam has been
shown to be a valuable addition to currently available
regiments when used alone in the treatment of acute alcohol
withdrawal, especially during the initial period where anxi-
ety and insomnia related symptoms are at their peak [5]. The
major metabolic pathway of this benzodiazepine in humans
involves removal of the N-1 methyl group, resulting in the
formation of the main pharmacologically active metabolite
desmethylclobazam [6–8] (Fig. 1).
Several methods for the determination of clobazam
have been published. Immunoassay [8] approaches remain
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extremely useful for initial screening. Although gas chro-
matography [9] is much more sensitive and specific, it
requires derivatization procedures and thermolabile benzo-
diazepines are not suited to this technique. As a consequence
high-performance liquid chromatography (HPLC) [10–19]
and more recently, the coupling of HPLC with mass spectro-
metry (MSD) [20,21] provides a useful and robust technique
for the analysis of benzodiazepines.
In this study, we report a fatal case involving clobazam in
high concentration and the identification of its metabolite in
the post-mortem blood sample. An HPLC/diode array detec-
tor (DAD)/MSD with an electrospray source in positive
mode was developed in order to detect, confirm and quantify
this benzodiazepine in the post-mortem samples.
2. Case report
A 49-year-old Caucasian female was found dead by her
husband, at home, lying on the floor of the bathroom. The
forensic pathologist was called to perform a scene examina-
tion and to verify the time of death. Traces of vomit with no
obvious smell and diarrhoea were present. Many different
drugs were found in her bedroom: clobazam, bromazepam,
zolpidem, fluoxetine, ranitidine and dissulfiram. She had
been undergoing long term psychiatric treatment and had a
history of chronic alcoholism. On the day of her death she
had been seen at the hospital, by her psychiatrist.
Autopsy was performed 3 days after death at the Forensic
Pathology Service of the Coimbra Delegation of the
National Institute of Legal Medicine (NILM). At the
autopsy, an external examination revealed rash, eye conges-
tion, abrasions on the right lower extremity and echymoses
on the upper and lower extremities of the abdomen. The
internal examination revealed signs of visceral congestion,
hepatic steatosis and a small piece of a plastic blister pack in
the stomach. Microscopic findings showed focus of pneu-
monia, bronchitis and bronchiolitis, with intra-alveolar
hemorrhages and focal mild pulmonary edema. The kidneys
showed chronic tubular nephritis. Samples of the blood,
stomach, liver and kidney were taken for toxicological
analysis.
3. Materials and methods
3.1. Chemicals
Clobazam and prazepam (used as internal standard) were
supplied by Sigma–Aldrich-Chemie GmbH (Steinheim,
Germany). Each standard compound was dissolved in
methanol (1 mg/ml) and stored at 4 8C. All solvents were
analytical or HPLC grade and were purchased from E.
Merck (Darmstadt, Germany). Water was purified by a
Milli-Q system obtained from Millipore (Molsheim,































Fig. 1. Metabolic pathways for clobazam.
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dissolving 4.2 g of NaHCO3 into a 100 ml volumetric flask
and brought to volume with demonised water. The buffer
was stored refrigerated (4 8C). The mobile phase was filtered
with a 0.20 mm Schleicher & Schuell filter and degassed in
an ultrasonic bath for 15 min just before use.
3.2. Instrumentation
The chromatographic system used was a Waters 2695
Alliance System and a Symmetry1 C18 reversed-phase
column (2.1 mm i.d. 150 mm, 3.5 mm). A methanol/water
mobile phase gradient was used for compound separation,
programmed to be held at 55% methanol for 5 min and then
increased to 65% over 12 min, followed by a hold at 55%
methanol for 5 min. A 5 min reconditioning time was
allowed before the next injection. The total run time was
30 min at a flow rate of 0.250 ml/min. The separation was
performed at 25 8C. The injection volume was 5 ml.
For detection, a Waters 996 photodiode array detector was
used, operated on a 210–400 nm wavelength scan with a
1.2 nm resolution. The UV absorbance was measured at
254 nm. Instrument control, data acquisition and processing
were achieved by the use of Waters Empower software
(Milford, MA).
Mass spectrometry detection was carried out by a Waters
ZQ 2000 mass spectrometer with an electrospray ionisation
(ESI) performed in positive mode. Full-scan spectra were
recorded from m/z 180–380, at a scan time of 0.5 s and an
interscan delay of 0.1 s. The mass spectra were represented
in centroid mode. The other main instrument settings were:
capillary voltage 3.5 kV; cone voltage 45 V; extractor 3 V;
ion energy 0.1; source temperature 80 8C; desolvation tem-
perature 150 8C; cone gas (N2) flow rate 50 l/h and desolva-
tion gas (N2) flow rate 250 l/h.
Quantitation made use of the selected ion-recording mode
(SIR) using the most abundant characteristic ion [M þ H]þ,
m/z 301 and the fragment ion, m/z 259, for confirmation.
The other drugs (zolpidem, fluoxetine, ranitidine and
disulfiram) were analysed by gas chromatography with a
mass spectrometry detector [22]. Ethanol was quantified by
conventional gas chromatography with a flame ionisation
detector and a headspace system (GC/FID/HS), using n-
propanol as internal standard.
3.3. Sample preparation
Control and calibration samples were prepared by
spiking drug-free post-mortem blood samples with standard
solutions.
A 1 ml aliquot of whole blood or 1 g of tissue (cut in small
pieces) was spiked with 20 ml of internal standard (praze-
pam, 100 mg/ml). Then 0.5 ml of carbonate buffer (50 mM)
was added to bring the sample to alkaline conditions (pH
10.5), followed by agitation in a vortex mixer.
Two liquid–liquid extractions were performed, one with
6 ml n-hexane: ethyl acetate (7:3, v/v) and the other with
6 ml n-hexane:2-propanol (99:1, v/v) in a rotamix device for
15 min. After centrifugation at 3000 rpm for 20 min. The
combined supernatant was evaporated to dryness under a
slow stream of nitrogen, at 40 8C.
The dried extracts were reconstituted with 250 ml metha-
nol and an aliquot (5 ml) was injected into the HPLC/DAD/
MSD system.
4. Results and discussion
Calibration curves were linear from 0.01 to 10 mg/ml.
Eight calibrators were used to generate a standard curve, in
triplicate. The calibration curves were constructed from peak
areas using the SIR mode and showed a linear relationship
for clobazam with a coefficient of correlation of 0.9988. Due
to the high clobazam concentration found in the presented
case, it was necessary to develop the method with a larger
concentration range.
The detection limit (LOD) was estimated from extracted
blood samples spiked with decreasing concentrations of
clobazam, where the response, of the protonated molecular
ion in SIR mode, was equivalent to three times the baseline
noise. The limit of quantitation (LOQ) was the lowest
amount of analyte in a sample that could be quantitatively
determined with a suitable precision and accuracy (coeffi-
cients of variability, CV < 20%).The LOD for clobazam was
1.0 ng/ml and LOQ, was 10.0 ng/ml.
Extraction recovery was determined by comparing the
representative peak areas of extracted drug-free blood spiked
before extraction with the peak area of drug-free blood
fortified before injection at the same concentration.
Table 1 shows that the calculated extraction efficiencies
for clobazam ranged from 76 to 99%. Intra-day and inter-
day coefficients of variability values were determined by
replicate analyses (n ¼ 5) of blood sample aliquots, either on
the same run (intra-day) or on separate days (inter-day). The
method proved to be precise for clobazam, both in terms of
intra-day and inter-day analysis, with coefficients of varia-
tion of less than 10%.
The chromatographic method described had a run time
of 30 min, and clobazam, was detected at a retention time of
6.7 min.
Table 1











0.05 76 8.3 9.7 5
0.1 88 5.7 4.5 5
1 97 3.1 4.9 5
2 92 3.4 5.3 5
5 99 2.2 3.5 5
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Since the procedure was found to be sensitive, selective
and reproducible, the developed method was applied to the
fatal case presented here. The toxicological analysis showed
clobazam concentrations of 3.9 mg/ml in the blood, 1.1 mg/g
in the stomach, 2.4 mg/g in the liver and 5.3 mg/g in the
kidney. Neither ethanol or other drugs were detected in the
post-mortem samples.
Quantitation employed the selected ion-recording mode
using the most abundant characteristic ion, m/z 301, and the
fragment ion, m/z 259, for confirmation. The fragmentation
voltage from 20 to 70 V was also investigated. On increasing
the fragmentation voltage, the clobazam fragmentation pat-
tern became more complex. The abundance of the molecular
ion [Mþ H]þ for this benzodiazepine decreased with higher
fragmentation voltages (>40 V) and the characteristic ions
appeared. Depending on the compound structure, the char-
acteristic ions appeared at different fragmentation voltages
[21]. The results of the positive electrospray ionisation mass
spectrum of clobazam with a cone voltage of 40 and 60 V,
obtained after injection of extracted blood samples, are
shown in Fig. 2.
The blood concentration of clobazam, in the fatal case,
was 3.9 mg/ml, which is much higher than the reported
therapeutic level (0.1–0.4 mg/ml) [23]. However, it is a fact
that in assessing whether benzodiazepines have contributed
significantly to a death, it is essential to have access to a full
medical history and a detailed record of the autopsy findings
[24]. The main pharmacologically active metabolite des-
methylclobazam was also detected (Fig. 3), but was not
quantified due to the lack of the corresponding standard.
However, given that it is obviously an important metabolite
which is rapidly formed from clobazam and usually the
major species present, even in overdoses, the clobazam
concentration found in blood is sufficient to allow some
conclusions to be reached concerning intoxication since the
authors [24] who have reported the only documented case of
clobazam intoxication achieved a lower concentration of
clobazam and did not even refer to the detection of its
metabolite. These authors reported a fatal case caused by
an overdose of clobazam and diazepam, in a man who
developed bronchopneumonia, with a clobazam concentra-
tion of 1.5 mg/ml in post-mortem blood. This is also a case
where other drugs, including ethanol, did not contribute to
the death. It is particularly significant to note that bronch-
opneumonia was also found in our case. Indeed the devel-
opment of bronchopneumonia is recognised as being
associated with immobility and coma, whether drug induced
or otherwise. [24,25], and thus, it is important to emphasise
the fact that the sedatives may contribute to the development
of pneumonia, which can have the additional effect of
producing a toxaemia. On the other hand, some authors
[24] also claim that some of the individuals shown to have
bronchopneumonia in association with the injection of
benzodiazepines prior to death, suggests that there is a
period of survival following drug injection and excretion
of drugs may occur resulting in the lowering of post-mortem
drug concentrations.
Clobazam was also detected in other tissues, which could
reveal a possible re-distribution phenomenon. Postmortem
drug redistribution has been reported for many drugs [26–
31], but few have assessed whether benzodiazepines in
general undergo post-mortem redistribution [26,27,29–31].
The process of redistribution can affect the concentration of
all analytes in post-mortem blood as a result of the disruption
of cellular membranes, causing alterations of drug concen-
trations within tissue elements and diffusion from one tissue
to another. This process is particularly significant for drugs
with high lipid solubility or high tissue concentrations
relative to blood [31]. In cases in which significant residues
were still present in gastric contents there was no apparent
increase in blood concentrations of nitrobenzodiazepines
and metabolites. Therefore, some authors concluded that
post-mortem diffusion into peripheral blood is not a con-
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Fig. 2. Positive ESI mass spectrum of clobazam: cone voltage of
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Fig. 3. Positive ESI mass spectrum of desmethylclobazam: cone
voltage of 65 V.
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5. Conclusion
As a result of the background circumstances and the
autopsy findings, it was concluded that clobazam was
responsible for the death, probably by respiratory depres-
sion. When poisoning occurs, respiratory depression and
pneumonia are present [24,26], as seen in this case, includ-
ing bronchopneumonia, bronchitis and bronchiolitis.
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